Alnylam Pharmaceuticals
ALNY
#608
Rank
NZ$70.37 B
Marketcap
NZ$527.47
Share price
-3.27%
Change (1 day)
35.98%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): NZ$3.13

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$3.07. In 2023 the company made an earnings per share (EPS) of NZ-$6.01 an increase over its 2022 EPS that were of NZ-$15.82.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$3.13
2023NZ-$6.01-62%
2022NZ-$15.8229.03%
2021NZ-$12.26-3.36%
2020NZ-$12.69-8.48%
2019NZ-$13.877.67%
2018NZ-$12.8839.74%
2017NZ-$9.2212.94%
2016NZ-$8.1638.84%
2015NZ-$5.88-32.88%
2014NZ-$8.76259.44%
2013NZ-$2.44-31.25%
2012NZ-$3.54

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$12.26 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$3.52 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$73.45 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.67-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.24-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.41-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.11-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.60-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA